Skip to main content

News & Events

Events Calendar

TCM BioBreakfast Series: The Commercial Implications of Personalized Medicine

MdBio Division of the Tech Council of Maryland
Center for Advanced Research in Biotechnology (CARB)
9600 Gudelsky Drive
Auditorium, Room A-107
United States
7:30am to 10:30am

“Personalized medicine is one of the best ways to improve quality and efficiency in healthcare, and reduce costs”, states Brook Byers, a managing partner in the VC firm Kleiner Perkins Caulfield and Byers.

The wealth of information made possible by advancements in genomic science is paving the way for the development of “targeted” diagnostic tests and therapeutics based on an individual’s genetic profile.  This personalized medicine approach holds the potential to revolutionize healthcare by selecting the “right treatment for the right person at the right time”.   What are the commercial opportunities and regulatory challenges posed by the personalized medicine revolution?  And how will this revolution shape the strategies of companies engaged in the development of drugs and diagnostics?

This BioBreakfast program features a panel of preeminent experts who will share some of the exciting commercial breakthroughs as well as the regulatory and legislative developments expected to affect the advancement of personalized medicine in the near-term.  We are pleased to welcome Dr. Janet Woodcock, the FDA’s Director of the Center for Drug Evaluation and Research, as a special guest.  Register now for this timely and informative discussion.


Dr. Stephen Little
Vice President, Personalized Healthcare

Eric K. Rowinsky, M.D.
Chief Medical Officer
Champions Biotechnology

Christopher Wasden
Managing Director, Strategy and Innovation
Pricewaterhouse Coopers

Janet Woodcock, M.D.
Director, Center for Drug Evaluation and Research
U.S. Food and Drug Administration


Karen Lovitch
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.